150 Participants NeededMy employer runs this trial
Hetrombopag Olamine for Low Platelet Count
Recruiting at 6 trial locations
JX
Overseen ByJunye Xiong
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
What You Need to Know Before You Apply
What is the purpose of this trial?
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Are You a Good Fit for This Trial?
Inclusion Criteria
Signed ICF for voluntary participation in the study and good compliance
Life expectancy ≥6 months
I am fully active or can care for myself with little or no help.
See 3 more
Exclusion Criteria
I have had severe bleeding during the screening period.
I do not have an active or uncontrolled hepatitis B or C infection.
I have a blood cancer.
See 8 more
What Are the Treatments Tested in This Trial?
Interventions
- Hetrombopag Olamine
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Group I: Part B：Hetrombopag Olamine vs Hetrombopag Olamine PlaceboExperimental Treatment1 Intervention
Group II: Part A: Hetrombopag OlamineExperimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jiangsu HengRui Medicine Co., Ltd.
Lead Sponsor
Trials
663
Recruited
102,000+
Founded
1970
Headquarters
Lianyungang, China
Known For
Oncology Innovations
Top Products
Camrelizumab, Rivoceranib (Apatinib)
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.